Evidence map›Paper›PMID 40172782›Full record

SynthesisIrish journal of medical science2025

Safety and efficacy of prusogliptin in type-2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.

Abdul Moeed, Muhammad Ahmed Ali Fahim, Afia Salman, Tooba Saqib, Laiba Zafar, Hoorain Jamil, Alishba Adnan Janjua, Syed Muhammad Muneeb Akhtar, Hamna Ahmed Khan, Hajra Zainab Chaudry and 6 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Abdul MoeedDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, 74200, Sindh, Pakistan.
Muhammad Ahmed Ali FahimDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, 74200, Sindh, Pakistan. faua857@gmail.com.ORCID http://orcid.org/0009-0006-1468-4388
Afia SalmanDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, 74200, Sindh, Pakistan.
Tooba SaqibDepartment of Internal Medicine, King Edward Medical University, Lahore, 5400, Punjab, Pakistan.
Laiba ZafarDepartment of Internal Medicine, King Edward Medical University, Lahore, 5400, Punjab, Pakistan.
Hoorain JamilDepartment of Internal Medicine, King Edward Medical University, Lahore, 5400, Punjab, Pakistan.
Alishba Adnan JanjuaDepartment of Internal Medicine, King Edward Medical University, Lahore, 5400, Punjab, Pakistan.
Syed Muhammad Muneeb AkhtarDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, 74200, Sindh, Pakistan.
Hamna Ahmed KhanDepartment of Internal Medicine, King Edward Medical University, Lahore, 5400, Punjab, Pakistan.
Hajra Zainab ChaudryDepartment of Internal Medicine, King Edward Medical University, Lahore, 5400, Punjab, Pakistan.
Ayesha AliDepartment of Internal Medicine, King Edward Medical University, Lahore, 5400, Punjab, Pakistan.
Laiba SanoberDepartment of Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, 75660, Sindh, Pakistan.
Muqaddas ParvezDepartment of Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, 75660, Sindh, Pakistan.
Hala NajeebDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, 74200, Sindh, Pakistan.
Abdul Hannan SiddiquiDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, 74200, Sindh, Pakistan.
Salim SuraniMedicine & Pharmacology, Texas A&M University, College Station, TX, 77843, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to conduct a systematic review and meta-analysis of the currently present literature analyzing the effectiveness and safety profile of prusogliptin, a novel dipeptidyl peptidase-IV (DPP-4) inhibitor, as compared to placebo in type 2 diabetes mellitus (T2DM) patients.

methodsThis systemic review and meta-analysis complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search strategy based on various MeSH terms was run on: PubMed/Medline, SCOPUS, and Cochrane Central, which were then systematically searched from inception till March 2024 to select all relevant Randomized Control Trials (RCT).

resultsThe analysis of the findings from three RCTs with 957 patients revealed that prusogliptin reduced Hemoglobin A1c (HbA1c)% levels in T2DM patients significantly [Mean Difference (MD): -0.62, 95% Confidence Interval (CI): -0.74 to -0.50, I

conclusionPrusogliptin has a favorable efficacy in attaining glycemic control in patients with T2DM. However, its safety profile yields uncertain outcomes. More literature is required for a definitive result.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsPiperidonesGlycated HemoglobinHumansPiperazinesPiperidinesRandomized Controlled Trials as TopicTreatment Outcome4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-oneDipeptidyl-Peptidase IV InhibitorsGlycated HemoglobinHypoglycemic AgentsPiperazinesPiperidinesPiperidonesDBPR108PrusogliptinType 2 diabetes mellitusWeight loss

Identifiers

PMID40172782

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.